Investor Relations

JUNE 27, 2011 | Creathor Venture accelerates growth of SIRION BIOTECH with further investment

Creathor Venture and current investors invest in SIRION BIOTECH and provide further funding. In addition to Creathor Venture the investors High-Tech-Gründerfonds, KfW, and Bayernkapital also joined the current round to further fund the young Munich based biotech. SIRION's core competence lies in the development and marketing of adenoviral and lentiviral vector technologies in the field of target validation.

Press release in English
Press release in German

Nov 2009 | SIRION BIOTECH receives growth financing from Creathor Venture, Bayernkapital, KFW and High-Tech-Gründer-Fonds (HTGF)

The funding will help SIRION BIOTECH to enhance their activities in foreign markets and to accelerate the speed of developing products in the area of adenovirus vector technology.

Oct 2009 | SIRION BIOTECH together with Helmholtz Zentrum Munich (HGMU) receives funding from BMWi for finding new therapeutic approaches in leukemia

In the two years cooperation project funded with approx. 300 tEUR SIRION BIOTECH will facilitate viral delivery of siRNAs to hematopoietic cells which HGMU will use for target validation in leukemia research.

Nov 2008 | SIRION BIOTECH receives a financing from Clusterfond Start up! of Bayernkapital with Creathor Venture and KFW being co-investors

After having received a High Tech Gründerfond (HTGF) financing in 2007 the company has approved the market acceptance of their services and products in the sector of genetically modified cells and vector systems. The new financing round with Clusterfond Start up! being in the lead investor is intended for accelerating the pace of the market entry.

NOV 2006 | SIRION started in new laboratories

SIRION started in new laboratories in IZB in Martinsried its service and product business in providing gene function tools.